Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST RA trial of filgotinib versus intramuscular triamcinolone bridging in newly diagnosed rheumatoid arthritis
NL-OMON59205Phase 4Not yet recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Medisch Spectrum Twente. Primary endpoint: Remission at 3 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON59205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59205.